Indication assessment · §3
Biological ageing and healthspan endpoints — trial records
Trial records in the Institute's register bearing on biological ageing and healthspan endpoints.
§3Trials in this indication
4 trial records in the Institute's register bear on this indication, of which 1 is a published trial.
Table 2. Trial records bearing on biological ageing and healthspan endpoints.
| Record | Compound | Phase | Design | Randomised | Year |
|---|---|---|---|---|---|
| EPI-RU-ELDERLY | Epithalon | — | Observational | — | — |
| EPI-RU-ELDERLY-PKprogramme record | Epithalon | Phase 1 | Phase 1 ascending dose | — | — |
| EPI-RU-ELDERLY-RENAL-IMPprogramme record | Epithalon | Phase 1 | Phase 1 ascending dose | — | — |
| EPI-RU-ELDERLY-BODY-COMPprogramme record | Epithalon | — | Randomised, double-blind, placebo-controlled | — | — |
| This facet in the trial register. | |||||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Khavinson VK, Kuznik BI, Tarnovskaya SI, Linkova NS. Peptides and CCL11 and HMGB1 as differently expressed age-dependent proinflammatory biomarkers of ageing. Advances in Gerontology 2020;10(1):1–8. identifier not held by the Institute The digital object identifier previously carried on this record did not resolve and has been withdrawn. Journal and year are retained.
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.
Compound Evidence Institute · CEI-IN-30/3 · https://compoundevidence.com/indications/longevity/trials/ · retrieved 30 July 2026